UBiENCE Inc. announced that it expects to receive ¥100 million in funding from D. Western Therapeutics Institute, Inc.
June 16, 2021
Share
UBiENCE Inc. announced that that it will receive ¥100 million in an equity round of funding on June 17, 2021. The transaction will include participation from new investor D. Western Therapeutics Institute, Inc. (JASDAQ:4576) for 18.9% stake in the company. The transaction has been approved by the board of directors of D. Western Therapeutics Institute, Inc. (JASDAQ:4576). The transaction is expected to close on June 30, 2021.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 